Pegylated interferons for the treatment of chronic hepatitis C infection.
about
Designing cell-targeted therapeutic proteins reveals the interplay between domain connectivity and cell bindingPromising candidates for the treatment of chronic hepatitis C.Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transferSafety, Tolerability, and Immunogenicity of InterferonsTreatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelingBiodegradable nanogels for oral delivery of interferon for norovirus infectionProtein-polymer conjugates: synthetic approaches by controlled radical polymerizations and interesting applications.Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.Hepatitis C virus therapies: current treatments, targets and future perspectives.Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection.Peginterferon-alpha(2b) and ribavirin.Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway.Pegylated IFNs for chronic hepatitis C: an update.Chronic hepatitis C virus management: 2000-2005 update.Viral kinetics in the treatment of chronic hepatitis C.Improving anti-hepatitis C virus therapy.Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.Clinical improvement of diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: case report and review of the literature.A radiopaque polymer hydrogel used as a fiducial marker in gynecologic-cancer patients receiving brachytherapy.Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.Control of HIV infection by IFN-α: implications for latency and a cure.High-Resolution Imaging of Polyethylene Glycol Coated Dendrimers via Combined Atomic Force and Scanning Tunneling Microscopy.Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression.Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic.Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α-2a.Living with hepatitis C and treatment: the personal experiences of patients.Electrospun micelles/drug-loaded nanofibers for time-programmed multi-agent release.
P2860
Q28252009-0634F022-C9B6-4DF0-BBA8-EA2A66BE5718Q30333233-D281B350-C579-44B5-9248-CFD6B37F332DQ33296224-13EED666-7008-43A7-9A31-145376A4FD5BQ33435810-686C75E5-687C-4834-B010-FCECD54BF218Q33899320-43AC2E50-6186-4D12-85FA-F30249DDE5A5Q34525191-5CC4D0E4-2800-41EC-8812-8AFC2510D7E1Q34716081-BEE724E7-4A80-42B5-BEF6-0B2FD3342176Q35011072-433D4B86-0E51-4959-9C80-91DD8EB06754Q35147050-308C8549-48B2-410A-8452-07FA2D0B7165Q35205389-3CC7E7C2-6AF1-4C15-B45F-B5A0D7B84F8EQ35917315-CD57C34E-6A8D-4FDF-9909-EF52EE4B47FAQ36007339-F7BF12E3-478B-4856-9D3E-36BE3F2FAA6BQ36316698-6E81F40D-FB46-4914-9104-0FAD494F81BFQ36348376-4DC9BB5A-147E-43D1-BC67-4040F568C7FDQ36562168-30F4D192-A7DE-41B6-B429-A177BF56B7F7Q36569749-7DFC4674-682E-44D1-A7DE-2F528780EE7AQ36771385-09ADC0D3-E483-4D4C-B60E-8E3B69737E9AQ36929711-678F0156-709D-4ADB-B275-DC0EFF78C360Q37023070-D5D0AD31-9D37-4754-8E83-9B51A8EDB8E2Q38970639-5FBDA942-ED31-45A8-A7A0-9E77EAEE393DQ40481236-066D7120-FCFA-451A-AFDE-3C22671EA39CQ41922021-F2ADD04D-7F64-4B42-8A7E-60281E99083BQ42138880-20283366-ED7D-4DC9-B904-01C9C65E8FC2Q43032263-6FE7570F-5CB0-463A-8539-2DE9820B3906Q43040757-E7CC2F33-C792-4DAE-9E4A-A385342876B5Q45227683-DC0AB0A2-B2E0-455A-8132-F395AE52CE9EQ45423867-8F2F9EFE-B505-4FB1-9F24-DD8BDB734286Q45830250-9D8591E1-4F4F-4D19-A340-561F8D9DCA8CQ49140465-29BC309B-02EF-476F-8C08-A419F7EA128FQ53597147-1D4588E5-9E96-48DF-A11B-A4F2A52329E3
P2860
Pegylated interferons for the treatment of chronic hepatitis C infection.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Pegylated interferons for the treatment of chronic hepatitis C infection.
@ast
Pegylated interferons for the treatment of chronic hepatitis C infection.
@en
Pegylated interferons for the treatment of chronic hepatitis C infection.
@nl
type
label
Pegylated interferons for the treatment of chronic hepatitis C infection.
@ast
Pegylated interferons for the treatment of chronic hepatitis C infection.
@en
Pegylated interferons for the treatment of chronic hepatitis C infection.
@nl
prefLabel
Pegylated interferons for the treatment of chronic hepatitis C infection.
@ast
Pegylated interferons for the treatment of chronic hepatitis C infection.
@en
Pegylated interferons for the treatment of chronic hepatitis C infection.
@nl
P2093
P1476
Pegylated interferons for the treatment of chronic hepatitis C infection.
@en
P2093
Bruce A Luxon
Diana Brassard
Michael Grace
Ronald Bordens
P304
P356
10.1016/S0149-2918(02)80042-X
P577
2002-09-01T00:00:00Z